Quisel John D sold $2.5M of IRON
Quisel John D (Chief Executive Officer) sold 33,000 shares of Disc Medicine, Inc. (IRON) at an average of $74.96 ($74.27–$76.05, $2.47M total) across 3 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the disclosed open-market sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan; no new company fundamentals are provided.
Market read
Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a fundamental repricing.
What to watch
The article does not state whether the CEO’s remaining holdings changed materially versus prior plans, nor does it provide context on prior sale cadence or any concurrent company news.
Background
The article is an SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).
Ticker impact
Disc Medicine CEO Quisel John D sold about 33,000 shares in open-market transactions totaling $2.47M, per a fresh SEC Form 4 filed today.
Likely limited near-term impact; any effect would be sentiment-driven rather than a new business catalyst.
The filing is primary-source and time-stamped, but the article provides no new operational, regulatory, or financial development beyond the sale itself, and it explicitly states a pre-arranged 10b5-1 plan.
Market effects
Minimal; insider sale does not disclose sector-wide changes.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can be purely mechanical and may not signal reduced confidence; traders may discount it versus other catalysts.
Key entities
- issuerDisc Medicine, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderQuisel John D
CEO and director who sold shares under a 10b5-1 plan.